Abstract
Cocaine, as an indirect dopamine agonist, induces selective behavioral and physiological events such as hyperlocomotion and dopamine release. These changes are considered as consequences of cocaine-induced molecular adaptation such as CREB and c-Fos. Recently, methanolic extracts from licorice was reported to decrease cocaine-induced dopamine release and c-Fos expression in the nucleus accumbens. In the present study, we investigated the effects of liquiritigenin (LQ), a main compound of licorice, on acute cocaine-induced behavioral and molecular changes in rats. LQ attenuated acute cocaine-induced hyperlocomotion in dose-dependent manner. In addition, LQ inhibited CREB phosphorylation and c-Fos expression in the striatum and the nucleus accumbens induced by acute cocaine. Results provide strong evidence that LQ effectively attenuates the acute behavioral effects of cocaine exposure and prevents the induction of selective neuroadaptive changes in dopaminergic signaling pathways. Further investigation of LQ from licorice extract might provide a novel therapeutic strategy for the treatment of cocaine addiction.
Keywords: Liquiritigenin, cocaine, hyperlocomotion, CREB, c-Fos, nucleus accumbens, striatum, postsynaptic D1/D2-like dopamine, postsynaptic neuronal
Current Neuropharmacology
Title: Liquiritigenin Decreases Selective Molecular and Behavioral Effects of Cocaine in Rodents
Volume: 9 Issue: 1
Author(s): E. Y. Jang, M. Hwang, S. S. Yoon, J. R. Lee, K. J. Kim, H.-C. Kim and C. H. Yang
Affiliation:
Keywords: Liquiritigenin, cocaine, hyperlocomotion, CREB, c-Fos, nucleus accumbens, striatum, postsynaptic D1/D2-like dopamine, postsynaptic neuronal
Abstract: Cocaine, as an indirect dopamine agonist, induces selective behavioral and physiological events such as hyperlocomotion and dopamine release. These changes are considered as consequences of cocaine-induced molecular adaptation such as CREB and c-Fos. Recently, methanolic extracts from licorice was reported to decrease cocaine-induced dopamine release and c-Fos expression in the nucleus accumbens. In the present study, we investigated the effects of liquiritigenin (LQ), a main compound of licorice, on acute cocaine-induced behavioral and molecular changes in rats. LQ attenuated acute cocaine-induced hyperlocomotion in dose-dependent manner. In addition, LQ inhibited CREB phosphorylation and c-Fos expression in the striatum and the nucleus accumbens induced by acute cocaine. Results provide strong evidence that LQ effectively attenuates the acute behavioral effects of cocaine exposure and prevents the induction of selective neuroadaptive changes in dopaminergic signaling pathways. Further investigation of LQ from licorice extract might provide a novel therapeutic strategy for the treatment of cocaine addiction.
Export Options
About this article
Cite this article as:
Y. Jang E., Hwang M., S. Yoon S., R. Lee J., J. Kim K., Kim H.-C. and H. Yang C., Liquiritigenin Decreases Selective Molecular and Behavioral Effects of Cocaine in Rodents, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017371
DOI https://dx.doi.org/10.2174/157015911795017371 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Introduction to How Can the Children of World War II German National Socialist Sympathizers and Jewish Survivors Talk to Each Other
Adolescent Psychiatry Pharmacological Advances in the Treatment of Insomnia
Current Pharmaceutical Design GABAergic and Endocannabinoid Dysfunction in Anxiety - Future Therapeutic Targets?
Current Pharmaceutical Design Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Endogenous Cannabinoid and Opioid Systems and their Role in Nicotine Addiction
Current Drug Targets Editorial [Hot Topic: Sigma Receptor Research: Progress Towards Diagnostic and Therapeutic Uses of Sigma Ligands (Executive Guest Editor: Carmen Abate )]
Current Pharmaceutical Design Inflammation, Sleep, Obesity and Cardiovascular Disease.
Current Vascular Pharmacology Sildenafil Plasma Concentrations in Two HIV Patients with Pulmonary Hypertension Treated with Ritonavir-Boosted Protease Inhibitors
Current HIV Research Ligand and Structure-Based Drug Design as Strategies for the Screening of New BACE1 Inhibitor Candidates
Current Physical Chemistry The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Autism Spectrum Disorders: Etiology and Pharmacotherapy
Current Drug Therapy SNP-Mediated Neuroprotection under Glucose Deprivation Is Enhanced by Hypericum perforatum
CNS & Neurological Disorders - Drug Targets Functional Magnetic Resonance Imaging in Abstinent MDMA Users: A Review
Current Drug Abuse Reviews Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy
Mini-Reviews in Medicinal Chemistry Adenosine Receptor Modeling: What Does the A2A Crystal Structure Tell Us?
Current Topics in Medicinal Chemistry Identification of New Inhibitors for Human SIRT1: An in-silico Approach
Medicinal Chemistry Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews Development and Validation of a Fluorescence-Based HTS Assay for the Identification of P/Q-Type Calcium Channel Blockers
Combinatorial Chemistry & High Throughput Screening Opioid Antagonists for Pharmacological Treatment of Gambling Disorder: Are they Relevant?
Current Neuropharmacology